End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study

Lymphoma

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Ann Oncol

Michot JM, Bologna S, Bastie JN, Borght TV, Brière J, Ribrag V, Bommier C, Peyrade F, Lebras L, Damaj G, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquières H, Fruchart C, Soussain C, Becker S, Olivier P, Julian A, Molina T, Haioun C, Tilly H

doi: 10.1016/j.annonc.2025.11.006

Lymphoma

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns

Haematologica

Stuver R, Moore ZR, Barta SK, Bhansali RS, Choa R, Epstein-Peterson ZD, Ganesan N, Ghione P, Jain S, Jacobsen E, Johnson WT, Lukowski JD, Lunning M, McCabe S, Merrill M, Moskowitz AJ, Singh S, Taranto E, Yahalom J, Savage KJ, Imber BS, Horwitz SM

doi: 10.3324/haematol.2026.300853

Lymphoma

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Blood

Sorial MN, Malpica L, Chiattone CS, Julia E, Bachy E, Barta SK, Stuver RN, Jacobsen ED, Federico M, Jain H Dr, Prince HM, Foss FM, Zinzani PL, Okatani T, Kim WSS, Verburgh E, Al-Mansour M, Cabrera ME, Bhagat G, Shah D, Shen C, Jain S

doi: 10.1182/blood.2025030149

Lymphoma

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Br J Haematol

Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF

doi: 10.1111/bjh.70020

Lymphoma

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Br J Haematol

Mikhaeel NG, Bouziana S, Northend M, Brady JL, Sanderson R, Sivabalasingham S, Springell D, Roddie C, Bourlon C, Farias MC, Davila AM, Benjamin R, Patten PEM, Kumar E, Yallop D, Hwang A, Kamat S, Ntentas G, Kuhnl A

doi: 10.1111/bjh.70653

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Lymphoma

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group

Eur J Cancer

Ostrowska B, Domanska-Czyz K, Giza A, Taszner M, Tomaszewska A, Targonski L, Dabrowska-Iwanicka A, Poplawska L, Konecki R, Kotarska M, Szymanski M, Borawska A, Swierkowska M, Druzd-Sitek A, Paszkiewicz-Kozik E, Mroz-Zycinska E, Zimowska-Curyło D, Owczarek-Kaczmarek J, Drozd-Sokolowska J, Tajer J, Osiadacz W, Rymkiewicz G, Michalski W, Basak G, Krzanowski J, Sacha T, Zaucha JM, Walewski J, Romejko-Jarosinska J

doi: 10.1016/j.ejca.2026.116789

Lymphoma

The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review

Leuk Lymphoma

Belghoul M, Kuhnl A, Chevassut T, Sanderson R, Mikhaeel G, Benjamin R, Patton P, Jones J

doi: 10.1080/10428194.2026.2685253

Lymphoma

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Eur J Cancer

Fabbri N, Casadei B, Chiappella A, Stella F, Donzelli L, Galli E, Riva M, Martino M, Barbui AM, Musso M, Farina M, Angelillo P, Cutini I, Santoro A, Cavallo F, Rivela P, Castellino A, Krampera M, Petruzzellis G, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL

doi: 10.1016/j.ejca.2026.116879

Related content

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group

The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study